Part of Taylor & Francis, features the latest news, opinions, insight and more on #regenerativemedicine, #cellandgenetherapy in partnership with @Regen_Med

London
Our new In Focus video breaks down why cryopreservation is a critical process step in cell therapy development and how optimized approaches can improve cell quality, streamline manufacturing and support clinical and commercial success >>> hubs.ly/Q04zh4X90
58
What's inside our cardiac regeneration eBook? 🔬Human-relevant research models 💉Innovative therapeutic strategies ⚛️Biomaterial and scaffold innovations 👩‍⚕️Translational insights Download your free copy today >>> hubs.ly/Q04xwCy-0
1
84
We're counting down the days to ESGCT 2026! Come and find us at booth I-08 to chat the team and enter our prize draw for a chance to win an iPad! 📱✨ In the meantime, with so much on the agenda, we've picked out the key themes an sessions we're most excited about >>> hubs.ly/Q04zhtCM0
70
📖Get your copy: hubs.ly/Q04xwBz30 Bridging the gap between lab and clinic, our latest eBook on cardiac regeneration offers valuable insights for researchers at every stage. From developing preclinical models to advancing therapeutic candidates toward clinical application, explore peer-reviewed content and expert perspectives shaping the future of cardiovascular medicine.
1
96
What's coming up at Cell and Gene Therapy International Europe 2026? Explore the diverse streams that Cell and Gene Therapy International Europe 2026 has to offer, located at the Hotel Palace Berlin (Berlin, Germany) from 3–5 November 2026. >>> hubs.ly/Q04yVHtn0
84
📖Editor’s picks: Journal highlights >>> Our Commissioning Editor Jasmine Hagan spotlights her top papers from recent issues, featuring cutting-edge developments that address significant clinical challenges with novel cell therapies, advanced manufacturing techniques, and sustainable biomaterials.
108
From engineered cardiac patches to cell therapies using mesenchymal and induced pluripotent stem cells >>> hubs.ly/Q04xwBlT0 Our latest eBook explores innovative therapeutic strategies addressing the heart's limited regenerative capacity. Get your free copy!
77
What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04yc-Qx0 > The FDA has approved clinical testing of University of Colorado Anschutz's experimental CAR-T therapy in adults with colorectal cancer and children with solid tumors > Cellectis has pivoted from allogeneic CAR-T therapies to focus on in vivo gene editing therapies for chronic diseases > Glidepath Health has emerged from stealth mode with an AI-driven platform for managing cell and gene therapy logistics
139
What if muscle cells hold the key to stopping fibrosis? Cook MyoSite's latest research uncovers the cellular crosstalk that keeps damaged muscle from turning into fat and scar tissue. This discovery could transform treatment for muscular dystrophy and volumetric muscle loss.  Download the White Paper now >>> hubs.ly/Q04xlBwJ0
116
Have you downloaded the whitepaper ‘Cellular crosstalk in muscle tissue regeneration: lessons from FAP differentiation’? Explore research from Cook MyoSite examining the crosstalk between skeletal muscle progenitor cells and fibro-adipogenic progenitor cells that suggests that signals released by healthy myotubes may help keep FAP cells in a less differentiated state.   Learn more here >>>hubs.ly/Q04xlByc0
75
There’s less than a week until Biotech Week Boston! Have you planned your sessions yet? Check out our top picks to help you plan your time, plus revisit some of our most popular articles to help spark those valuable conversations. Read here: hubs.ly/Q04xDyYx0 @BiotechWkBoston @CellTherapyIC #BiotechWeekBoston
83
Advancing cardiac regenerative medicine requires human-relevant research models that accurately replicate the heart's complex cellular interactions. Our latest eBook features cutting-edge tools including cardiac spheroids that mimic the beating heart and endothelial cell assays that model angiogenesis. Download now >>> hubs.ly/Q04xwz-Z0
1
1
159
High translational failure rates, oversimplified in vitro systems, and animal models that don't capture the complexity of human tumor biology are driving a fundamental shift in how we evaluate immune cell therapies before they reach patients.  Discover how preclinical models are evolving to bridge this gap >>> hubs.ly/Q04vFxW_0
66
From selecting the right model system to incorporating relevant microenvironmental factors, multiple considerations shape the quality and interpretability of your data. This infographic outlines six essential considerations to guide your preclinical model design, helping you build more biologically relevant systems that support robust immune cell therapy development >>> hubs.ly/Q04vFQKs0
96
Find out how a novel gene activation platform, half the size of its CRISPR-based counterpart, could revolutionize the deliverability of gene therapies that target gene expression >>> hubs.ly/Q04x7LYc0
114
🚨Don't miss our In Focus exploring how preclinical model systems can be used to support the development of immune cell therapies >>> hubs.ly/Q04vFPsP0
71
What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04x6Pkq0 > uniQure submitted regulatory applications for its Huntington’s disease gene therapy in the US and UK > Bristol Myers Squibb announced positive topline results from the registrational Phase II trial assessing its CAR-T therapy for quadruple-class exposed relapsed and refractory multiple myeloma > EpilepsyGTx and Viralgen have entered into a partnership to develop an epilepsy gene therapy
1
132
In our latest article, explore in vivo CAR-T programs currently in clinical trials and several that have been acquired by major pharmaceutical companies >>> hubs.ly/Q04x0FjX0
106